Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 6, 2012, Pages 873-878

  Mercadante, Sebastiano ^a,b  

^a LA MADDALENA CANCER CENTER   (Italy)

^b Anesthesia and Intensive Care Unit   (Italy)

Author keywords

Breakthrough pain; Opioids; Oral transmucosal fentanyl citrate

Indexed keywords

FENTANYL CITRATE; MORPHINE; OPIATE;

ABDOMINAL PAIN; ASTHENIA; BRADYCARDIA; BREAKTHROUGH PAIN; CANCER PAIN; CANCER PATIENT; CHRONIC PAIN; CONFUSION; CONSTIPATION; DIAPHORESIS; DIZZINESS; DRUG ABSORPTION; DRUG ABUSE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; EUPHORIA; FIRST PASS EFFECT; HALLUCINATION; HEADACHE; HOT FLUSH; HUMAN; HYPOVENTILATION; LOZENGE; MOUTH ULCER; NAUSEA; ORTHOSTATIC HYPOTENSION; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; SOMNOLENCE; SWEATING; VASODILATATION; VERTIGO; XEROSTOMIA;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; BREAKTHROUGH PAIN; CLINICAL TRIALS AS TOPIC; FENTANYL; HUMANS; MOUTH MUCOSA; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84858843884     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.663353     Document Type: Review

References (27)

1. Portenoy RK, Hagen NA. Breakthrough pain: Definition, prevalence and characteristics. Pain 1990;41:273-81. The first attempt to provide a definition for breakthrough cancer pain
2. Portenoy RK, Payne D, Jacobson P. Breakthrough pain: Characteristics and impact in patients with cancer pain. Pain 1999;81:129-34
3. Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: The challenge of its dosing. Crit Rev Oncol Hematol 2011;80:460-5
4. Zeppetella GB. Opioids for cancer breakthrough pain: A pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage 2008;35:563-7
5. Ashburn M, Streisand J. Oral trasmucosal fentanyl. Help or hindrance? Drug Saf 1994;11:295-300
6. Csaba N, Garcia-Fuentes M, Alonso MJ. The performance of nanocarriers for transmucosal drug delively. Expert Opin Drug Deliv 2006;91:463-78
7. Streisand J, Varvel J, Stanski DR, et al. Absorption and availability of moral trasmucosal fentanyl citrate. Anesthesiology 1991;75:223-9
8. Aronoff G, Brennan M, Pritchard D, Ginsberg B. Evidence-based pral transmucosal fentanyl citrate (OTFC) dosing guidelines. Pain Med 2005;6:305-14
9. Streisand JB, Busch MA, Egan TD, et al. Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology 1998;88:305-9. A pharmacokinetic study providing relevant data about OTF.C.
10. Lee M, Kern S, Kisicki J, Egan T. A pharmacokinetic study to compare two simultaneous 400 microg doses with a single 800 microg dose of oral transmucosal fentanyl citrate. J Pain Symptom Manage 2003;26:743-7
11. Egan T, Sharma A, Ashburn M, et al. Multiple dose pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers. Anesthesiology 2000;92:665-73. A pharmacokinetic study providing relevant data about OTF.C.
12. Kharasch E, Whittington D, Hoffer C. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucisal fenatnyl citrate. Anesthesiology 2004;101:729-37
13. Shaiova L, Lapin J, Manco L, et al. Tolerability and effects of two formulations of oral trasmucosal fentanyl citrate (OTFC;ACTIQ) in patients with radiation-induced oral mucositis. Support Care Cancer 2004;12:268-73
14. Davies A, Vriens J. Oral trasnsmucosal fentanyl citrate and xerostomia. J Pain Symptom Manage 2005;30:496-7
15. Farrar J, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: A randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998;90:611-16. The first placebo-controlled study of OTF.C.
16. Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: A controlled dose titration study. Pain 1999;79:303-12
17. Christie J, Simmonds M, Patt R, et al. Dose-titration multicenter study of transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998;16:3238-45
18. Coluzzi P, Schwartzberg L, Conroy J, et al. Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulphate immediate release (MSIR). Pain 2001;91:123-30. The first study comparing OTFC with oral morphine
19. Mercadante S, Villari P, Ferrera P, et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer 2007;96:1828-33. The first study comparing OTFC with an active substance, also showing that proportional doses are effective and safe
20. Mercadante S, Radbruck L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: An open-label, randomized, crossover trial. Curr Med Res Opin 2009;25:2805-15. Another study comparing OTFC with a more recent delivery systems
21. Davies AN, Dickman A, Reid C, et al. Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: Recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009;13:331-8
22. Hagen NA, Fisher K, Victorino C, Farrar JT. A titration strategy is needed to manage breakthrough cancer pain effectively: Observations from data pooled from three clinical trials. J Palliat Med 2007;10:47-55
23. Hanks GW, Nugent M, Higgs C, Busch M. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer; an open, multicentre, dose-titration and long-term use study. Palliat Med 2004;18:698-704
24. Burton AW, Driver L, Mendoza T, Syed G. Oral transmucosal citrate in the outpatient management of severe cancer pain crisis: A retrospective case series. Clin J Pain 2004;20:195-7
25. Payne R, Coluzzi P, Hart L, et al. Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage 2001;22:575-83
26. Mandel L, Carunchio MJ. Rampant caries from oral transmucosal fentanyl citrate lozenge abuse. J Am Dent Assoc 2011;142:405-9
27. Mercadante S. Fentanyl buccal tablet in breakthrough pain in opioid-tolerant patients with cancer: A viewpoint by Sebastiano Mercadante. Drugs 2006;66:2394-5